Immatics biotechnologies
Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. Learn more
Launch date
Employees
Market cap
$1.3b
Enterprise valuation
$742m (Public information from Sep 2024)
Share price
$12.16 IMTX
Company register number HRB 382151 (Stuttgart)
Tübingen Baden-Württemberg (HQ)
Authorizing premium user...